

# Haematological Perturbations in Human Immunodeficiency Virus (HIV) Positive Patients Receiving Antiretroviral Therapy in Edo State, Nigeria

## ABSTRACT

**Aim:** This study sought to investigate the haematological perturbations in HIV-positive patients undergoing antiretroviral therapy (ART) in Edo State, Nigeria.

**Methodology:** This prospective case-controlled study was conducted at the HIV clinic of the University of Benin Teaching Hospital. The research enrolled 150 HIV-positive patients and an equal number of sex and age-matched HIV-negative control subjects. Inclusion criteria encompassed individuals aged 18 years and older, confirmed HIV-positive, and receiving ART for at least six months. Exclusion criteria excluded those with sickle cell disorder, recent transfusions, or ongoing sepsis/malaria. Data collection involved self-administered questionnaires, HIV diagnosis via WHO-approved Nigerian National testing algorithms, and comprehensive haematological assessments. The obtained data were analysed using SPSS software, employing descriptive statistics and t-tests with a significance level of 0.05.

**Results:** Results revealed significant differences in demographic variables, duration of HIV infection, smoking history, and alcohol consumption between HIV-positive patients and control subjects. Furthermore, CD4<sup>+</sup> T lymphocyte counts showed substantial variations, indicating immunological differences. Haematological parameters such as hemoglobin levels, packed cell volume, white blood cell, platelet counts, and erythrocyte sedimentation rate exhibited statistically significant differences between the two groups. Additionally, a sub-analysis of HIV-positive patients based on CD4<sup>+</sup> T lymphocyte counts highlighted specific haematological changes associated with varying immunological statuses.

**Conclusion:** The findings underscore the impact of HIV and ART on haematological parameters, emphasizing the need for comprehensive monitoring and management strategies. This research contributes valuable insights into the context of HIV management in Nigeria, aiding healthcare professionals in optimizing patient care.

**Keywords:** Antiretroviral Therapy, CD4<sup>+</sup>T lymphocyte counts, Haematological perturbations, Human Immunodeficiency Virus

## 1. INTRODUCTION

Human immunodeficiency virus (HIV) infection causes acquired immune deficiency syndrome (AIDS) which is a late-stage disease [1]. HIV targets the immune system of the body, specifically the T lymphocytes, or CD4<sup>+</sup> T lymphocyte cells, which are part of the body's natural defence against infections [2]. The body becomes incapable of fighting off infections and illnesses as a result of HIV's gradual destruction of many of these T cells throughout infection. If HIV is left untreated, the body's T cell count decreases, which can lead to opportunistic infections or malignancies that prey on a weakened immune system,

ultimately cause AIDS [2]. Nigeria's adult general population's HIV prevalence was 1.5%, according to UNAIDS data from 2018 [3]. This figure is on the increase. An estimated 1.9 million individuals in Nigeria are infected with the virus [4]. According to reports, Nigeria has one of the highest rates of new HIV infections in Sub-Saharan Africa and the second-largest HIV epidemic worldwide [4].

Changes in the counts of peripheral blood cells in HIV infection cause haematological abnormalities, which are known to be highly reliable independent indicators of morbidity and death [5,6]. According to reports, these anomalies affect all three blood cell lineages and may result from both direct and indirect viral effects [7, 8]. According to previous studies, as the disease progresses, the haematological abnormalities in peripheral blood cell counts become more common and severe [5,8]. A variety of haematological disorders linked to HIV infection include impaired haematopoiesis, invasive bone marrow disease, splenomegaly-related peripheral blood cell destruction, cancers, immune-mediated cytopenias, and altered coagulation mechanisms [8]. According to literature, haematological abnormalities associated with HIV infection are among the most prevalent non-immunosuppressive side effects, and in patients who are new to therapy, they often manifest as cytopenias [9]. Anaemia is the most prevalent haematological aberration in HIV infections and a significant predictor of the development of AIDS, according to research [10,11].

Leucopenia and neutropenia in HIV infection have been documented in earlier researches [10–13]. While neutropenia renders HIV patients more vulnerable to bacterial infections, leucopenia is known to raise the prevalence of opportunistic infections [8]. According to reports, lymphopenia and low total lymphocyte counts are frequent outcomes of HIV infection [13–15]. In HIV positive individuals who do not exhibit any symptoms, thrombocytopenia is quite prevalent, according to previous studies [12, 13]. Venous thromboembolism and thrombotic thrombocytopenic purpura are well-known haematological consequences of HIV infection that have been observed in 1–5% and 2% of afflicted patients, respectively [16, 17].

An established surrogate marker and screening tool, the Erythrocyte Sedimentation Rate (ESR) is frequently employed in clinical practice to assess inflammatory or acute response, infection, trauma, autoimmune, and malignant disorders [18]. The ESR has been shown in earlier researches to be a significant predictor of the onset of AIDS [8,12].

An individual's total CD4<sup>+</sup> T cell count is quite valuable for assessing their immune system [19]. It is a crucial proxy sign for determining if an HIV-positive person is at risk of acquiring AIDS or contracting specific opportunistic illnesses [20]. HIV positive patients have been found to have low CD4<sup>+</sup> T cell numbers in earlier studies [5,8].

It is known that HIV infection is associated with significant haematological alterations that make patient care and treatment more difficult. Thus, understanding the haematological peripheral blood cell alterations in this cohort in our setting is crucial to provide comprehensive care and therapy that improves the quality of life for HIV-positive patients. This proposed study aims to assess the changes in the peripheral blood cell counts and the absolute CD4<sup>+</sup> T cell levels among HIV positive patients in Edo State, Nigeria.

## **2. RESEARCH METHODOLOGY**

### **2.1 Study Design**

This is a prospective case-controlled study carried out at the HIV clinic of the University of Benin Teaching Hospital (UBTH), a tertiary and referral health care facility in Edo State, Nigeria. The study protocol was approved by the hospital research and ethics committee and informed consent was obtained from subjects. By systematic selecting (simple random selection) of all the HIV positive patients attending UBTH Clinics, subjects who were 18 years of age and older were enrolled over a 6-month period (from April to October, 2023). Hospital employees, students, and traders were used as the control subjects.

## 2.2 Sample Size Determination

Sample size was calculated using the Fisher's formula as stated in Ekeleme et al. [21]:

$$n = \frac{Z^2(Pq)}{e^2}$$

where n = minimum sample size

Z = 1.96 at 95% confidence level,

P = known prevalence of HIV positive patients in Nigeria

e = error margin tolerated at 5% = 0.05

$$q = 1 - p$$

According to the Uduma et al. [22], the existing prevalence of HIV positive patients in Nigeria is approximately 10%.

$$P = 10\% = 0.1$$

$$q = 1 - p$$

$$= 1 - 0.1$$

$$= 0.9$$

$$n = \frac{(1.96)^2(0.1 \times 0.9)}{(0.05)^2}$$

$$n = \frac{0.345744}{0.0025} = 138.298$$

The minimum sample size was 138 and was adjusted to 150 to account for non-response rate of 10%.

One hundred and fifty (150) HIV positive patients receiving antiretroviral therapy (ART) were enrolled for the study. Also, one hundred and fifty (150) sex and age-matched HIV negative control subjects were recruited.

## 2.3 Inclusion criteria

Inclusion criteria of the patients for this study were age  $\geq$  18 years, confirmed for HIV infection, and receiving care at the ART clinic for at least 6 months were included in the study.

## 2.4 Exclusion criteria

Adults with known or features of sickle-cell disorder, or who were newly transfused in the last one month as well as those with ongoing sepsis/malaria (febrile, icteric, etc.) were excluded from the study.

## **2.5 Data Collection**

A self-administered questionnaire was used to gather sociodemographic and medical data from both HIV positive patients and control respondents. After pretest counselling and posttesting, the diagnosis of HIV was established by testing the capillary blood of the patients and the control subjects for antibodies to the virus. Rapid HIV testing was carried out using Determine TM HIV-1/2, Unigold, and Stat-Pak rapid kits in accordance with the WHO-approved Nigerian National Serial Testing Algorithm. HIV antibodies were tested for in the serial algorithm of serologic testing using two screening rapid test kits, Determine TM HIV-1/2 and Unigold, in that order. StatPack, a tiebreaker in inconclusive tests as described by Balogun et al. [23], and the Unigold fast kits were used to confirm a reactive sample to determine TM HIV-1/2.

Every HIV-positive patient was asked for their informed consent before 5 milliliters of whole venous blood were drawn from their cubital vein and placed into a vacutainer collecting tube containing potassium ethylenediaminetetra acetic acid (K-EDTA). A comparable volume of venous blood was drawn from HIV-negative, healthy control volunteers and placed into K-EDTA bottles. Every day, blood samples from the patients and the control group were analyzed using Cyflow R Counter for absolute CD4<sup>+</sup> T cell counts within six (6) hours of collection (Partec, Germany). Following the manufacturer's instructions, a Sysmex Kx-2IN Haematology autoanalyser (Sysmex Corporation, Japan) was used to perform complete blood cell counts on the same sample, including haemoglobin (Hb) levels, packed cell volume (PCV), total white blood cell (WBC), and platelet counts. As per the standard operating manual delineated by Balogun et al. [23], the erythrocyte sedimentation rate (ESR) of the samples was manually ascertained using the conventional Westergreen method.

## **2.6 Data Analysis**

The statistical package for the social science was used to analyze the collected data (version 20.0; SPSS, Chicago, IL). The mean, median, mode, and t-test were the statistical tests employed in this investigation. Simple tables containing frequencies, percentages, and mean values were used to display the obtained results. The threshold of statistical significance for group comparisons was set at P-value  $\leq 0.05$ .

## **3. RESULTS**

The distribution of gender among HIV patients and control subjects shows no significant difference (p-value  $> 0.05$ ). Significant differences in age distribution were observed among different age groups. The p-values for age groups "Less than 20" and "20 – 29" are less than 0.05, indicating a significant difference between HIV patients and control subjects in these age categories. Both smoking history and alcohol consumption show significant differences between HIV patients and control subjects (Table 1). CD4<sup>+</sup> T lymphocyte counts are significantly lower in HIV-positive patients compared to control subjects (p-value  $< 0.05$ ) (Table 2). All the haematological parameters (haemoglobin, PCV, WBC, Platelet and ESR) show significant differences between HIV-positive patients and control subjects (Table 3). Table 4 categorizes patients based on CD4<sup>+</sup>T cell counts and shows the distribution of haematological changes within each category.

**Table 1: Information of HIV positive Patients and Control Subjects**

Variables	HIV Patients n (%)	Control Subjects n (%)	p-value
<b>Gender</b>			
Male	68 (45.33)	70 (46.67)	0.803
Female	82 (54.67)	80 (53.33)	0.769
<b>Age (in Years)</b>			
Less than 20	3 (2.00)	5 (3.33)	0.014*
20 – 29	46 (30.67)	33 (22.00)	0.005*
30 – 39	21 (14.00)	27 (17.00)	0.155
40 – 49	45 (30.00)	49 (32.67)	0.674
50 – 59	26 (17.33)	25 (16.67)	0.733
60 and above	9 (6.00)	11 (7.33)	0.069
<b>Duration of HIV Infection</b>			
Less than 1 year	34 (22.67)	00 (0.00)	0.000*
1-5 years	70 (46.67)	00 (0.00)	0.000*
6-10 years	34 (22.67)	00 (0.00)	0.000*
More than 10 years	22 (14.67)	00 (0.00)	0.000*
<b>Smoking History</b>			
Current smoker	3 (2.00)	41 (27.33)	0.000*
Former smoker	38 (25.33)	22 (14.67)	0.000*
Never smoked	109 (72.67)	87 (58.00)	0.001*
<b>Frequency of alcohol consumption</b>			
Never	80 (53.33)	64 (42.67)	0.027*
Stopped alcohol	67 (44.67)	23 (15.33)	0.000*
Occasionally	3 (2.00)	39 (26.00)	0.000*
Regularly	0 (0.00)	24 (16.00)	0.000*

p-value  $\leq$  0.05 are statistically significant

**Table 2: CD4<sup>+</sup> T lymphocyte Count of HIV positive Patients and Control Subjects**

CD4 <sup>+</sup> T lymphocytes count/uL	HIV Patients	Control Subjects	p-value
Minimum	42	350	0.000*
Maximum	1082	1439	0.000*
Mean $\pm$ Stanard Deviation	361 $\pm$ 183	924 $\pm$ 97	0.000*

p-value  $\leq$  0.05 are statistically significant

**Table 3: Haematological variables of HIV positive Patients and Control Subjects**

Variables with cut off values	HIV Patients n (%)	Control Subjects n (%)	p-value
<b>Haemoglobin</b>			
<10 g/dL	51 (34.00)	00 (0.00)	0.000*
≥10 g/dL	99 (66.00)	150 (100.00)	0.000*
<b>PCV</b>			
<30%	48 (32.00)	00 (0.00)	0.000*
≥30%	102 (68.00)	150 (100.00)	0.000*
<b>WBC</b>			
<2/nL	14 (9.33)	00 (0.00)	0.000*
≥2/nL	136 (90.67)	150 (100.00)	0.000*
<b>Platelet</b>			
<100/nL	12 (8.00)	00 (0.00)	0.000*
≥100/nL	138 (92.00)	150 (100.00)	0.000*
<b>ESR</b>			
< 30 mm/hr	109 (72.67)	150 (100.00)	0.000*
≥ 30 mm/hr	41 (27.33)	00 (0.00)	0.000*

WBC = White Blood Cell, ESR = Erythrocyte Sedimentation Rate

p-value ≤ 0.05 are statistically significant

**Table 4: CD4<sup>+</sup> T lymphocyte counts and haematological changes among HIV positive Patients**

Haematological Parameters	CD4 <sup>+</sup> T lymphocyte counts			Total
	<200 (n = 63)	200 – 499 (n = 59)	≥500 (n = 28)	
Haemoglobin (< 10 g/dL)	36 (57.14%)	10 (16.95%)	5 (17.86%)	51
PCV (<30%)	39 (61.90%)	6 (10.17%)	3 (10.71%)	48
WBC (<2/nL)	9 (14.29%)	4 (6.78%)	1 (3.57%)	14
Platelet (<100/nL)	7 (11.11%)	3 (5.08%)	2 (7.14%)	12
ESR (≥ 30 mm/hr)	30 (47.62%)	8 (13.56%)	3 (10.71%)	41

WBC = White Blood Cell, ESR = Erythrocyte Sedimentation Rate

#### 4. DISCUSSION

The observed differences in age distribution among HIV-positive patients and control subjects may be indicative of the changing demographics of HIV infection. A higher prevalence of HIV among younger individuals could be attributed to various factors such as risky behaviours, lack of awareness, or inadequate preventive measures.

The significant differences in smoking history and alcohol consumption patterns align with previous studies linking these lifestyle factors to HIV progression and treatment outcomes. Previous research has established a strong association between smoking and accelerated progression to AIDS, as well as increased mortality rates among HIV-positive individuals

[24,25]. The higher prevalence of former smokers among HIV-positive patients in our study aligns with these findings, emphasizing the need for smoking cessation interventions in this population.

The association between alcohol consumption and compromised immune function in HIV-positive individuals has been well-established [26]. Our study corroborates these findings, showing a significant difference in the frequency of alcohol consumption between HIV-positive patients and control subjects. This underscores the importance of addressing alcohol use as part of comprehensive HIV care.

Consistent with the research by Cohen et al. [27] and Lundgren et al. [28], our study highlights the positive impact of early initiation of antiretroviral therapy on the duration of HIV infection. These findings emphasize the significance of early detection and treatment in improving clinical outcomes and reducing the burden of HIV-associated complications.

The observed variations in the duration of HIV infection highlight the importance of early detection and initiation of antiretroviral therapy. Studies have consistently shown that early treatment leads to better clinical outcomes and lower rates of HIV-associated complications [27,28].

The findings of this study (Table 2) align with previous research highlighting the impact of HIV infection on CD4<sup>+</sup> T lymphocyte counts. Studies conducted in different regions have consistently shown lower CD4<sup>+</sup> T lymphocyte counts in HIV-positive individuals compared to uninfected controls [29,30]. The mean CD4<sup>+</sup> T lymphocyte count of 361 cells/uL in HIV-positive patients receiving ART in Edo State is in line with global trends [31].

Moreover, the significant difference in CD4<sup>+</sup> T lymphocyte counts between HIV-positive patients and control subjects (p-value = 0.000\*) emphasizes the impact of HIV on the immune system, even with antiretroviral therapy. This underscores the importance of continuous monitoring and optimization of treatment regimens to ensure optimal immune reconstitution [32].

The results of this study (Table 3) align with previous research indicating that HIV infection and ART have profound effects on haematological parameters. The observed decrease in haemoglobin levels and packed cell volume (PCV) among HIV patients is consistent with findings from studies conducted in various regions [29,33]. These alterations may be attributed to factors such as chronic inflammation, nutritional deficiencies, or adverse effects of antiretroviral medications. This finding of the differences in the mean PCV values of the patients and controls also corroborates a previous report by De Carvalho et al. [7] in Pretoria, South Africa.

The present study's findings supported earlier observations [10,11] that anaemia is frequently associated with HIV infection. In this investigation, we discovered that patients with HIV who were extremely immunocompromised—that is, had an absolute CD4<sup>+</sup> T cell count of less than 200 cells/ $\mu$ l—had the highest prevalence of anaemia. This result supports earlier observations [10,13,15,34] showing anaemia is more common in HIV-positive patients with CD4<sup>+</sup> T cell counts < 200 cells/ $\mu$ l. According to reports, anaemia is more common when the level of CD4<sup>+</sup> T cells is less than 200 cells/ $\mu$ l, and it is also independently linked to a higher risk of passing away [34, 35]. It has been discovered that anaemia is the most frequent

haematological aberration in HIV infections and is a key sign that AIDS may eventually proceed [10,11,35].

HIV infection-related anaemia can be caused by a variety of factors, such as compromised haematopoiesis, immune-mediated processes, opportunistic infections, lymphoma, and the myelotoxic effects of antiretroviral medications [36, 37]. Hypoplasia of the bone marrow happens in advanced HIV infection [38]. Parvovirus B19, CMV, and mycobacterium avium complex are among the known opportunistic infections that either produce cytopenias or cause anaemia by intercurrent bone marrow suppression [39]. According to reports, normochromic normocytic and hypochromic microcytic anaemias are the most common kinds in HIV infections [5,8,12].

Results from related research [40,41] are corroborated by the decline in white blood cell count in HIV-positive people. Contributing factors to these alterations could be the immune dysregulation linked to HIV infection and the effect of ART on bone marrow function. Furthermore, research showing a connection between HIV and aberrant platelets and the thrombocytopenia seen in HIV patients is consistent with this observation [42].

Leucopenia (Total WBC of  $<2.0/nL$ ) was shown to be more common in HIV positive patients (9.33 percent) than in negative controls (0.00 percent) in this study. This result is similar to leucopenia prevalence estimates of 8 percent [23], 10 percent [12], but greater than 4.9 percent [5] and lower than 20.8 percent [13] among adult HIV positive patients who have not started on antiretroviral therapy. In a prior study, Chukwuezi et al. [43], similarly revealed that total white cell count was lower in HIV positive persons than in seronegative individuals.

In our study, 14.29 percent of the severely immunocompromised ( $CD4^+$  T cell  $< 200$  cells) HIV positive patients had leucopenia. This is extremely comparable to the 14.5 percent of antiretroviral therapy-naïve adult HIV positive patients in Lagos, Nigeria, described by Balogun et al. [23]. Comparable values of leucopenia (16.8%) in severely immunocompromised ART-naïve HIV positive patients have been reported by Parinitha et al. [10] in India, but Munyazesa et al. [13] in Rwanda reported a lower value of 8.4% among women. Leucopenia has been identified as the second most prevalent haematological defect in HIV infection [8] and raises the incidence of opportunistic infections in infected individuals. The virus's suppression of leucopoiesis, pathogenic organisms infiltrating the bone marrow, neoplasia, side medication effects, autoimmune neutropenia, and hypersplenism are among the factors that contribute to leucopenia in HIV infection [16].

At a cutoff of  $100/nL$ , the current study found that the proportion of thrombocytopenia in HIV patients was higher than in the control participants (8.00 percent vs. 0.00 percent,  $p = 0.000$ ). The obtained prevalence value is consistent with other research findings [13]. We found a thrombocytopenia prevalence of 11.11 percent among the critically immunocompromised individuals with a  $CD4^+$  T cell count of fewer than 200 cells. In highly immunocompromised treatment-naïve HIV positive individuals, a greater thrombocytopenia score of 21.7% was found in a prior Indian study [13]. Conversely, a lower thrombocytopenia value of 2.72 percent was found by Balogun et al. [23] among adult HIV positive patients in Lagos, Nigeria. Thrombocytopenia can come from either a decrease in platelet formation or an increase in platelet breakdown, which can be immune-mediated [17,44]. It can also be an early sign of HIV infection.

The ESR was found to be much greater in the patient group compared to the control group. This result supports other research findings that HIV positive patients' mean ESRs are statistically considerably higher than those of negative controls [8,12,13]. The ESR has been shown in earlier research to be a significant predictor of the onset of AIDS [8,12]. Increased erythrocyte count, inflammatory alterations, and PCV may all contribute to increased ESR in HIV-positive individuals [15]. The observed disparities could be explained by persistent inflammation, even in ART recipients [45]. The highest range of normal ESR in healthy adults, according to earlier research conducted in Nigeria, is 5.0 mm/hr for adult males and 12 mm/hr for adult females [46, 47]. In an earlier Nigerian study, Abdulqadir et al. [48] found that compared to HIV-negative pregnant women, HIV-positive pregnant women had a higher ESR but a mean lower haematocrit and absolute white cell count.

The mean absolute CD4<sup>+</sup> T cell counts in patients and controls were also observed to differ statistically significantly ( $p = 0.000$ ) at 361 and 924 cells/ $\mu\text{L}$ , respectively. These values matched published findings from earlier research [8,43]. The minimum CD4<sup>+</sup> T cell counts for the patients and controls in the current investigation were 42 and 350 cells/ $\mu\text{L}$ , respectively ( $p = 0.000$ ). HIV positive patients have also been shown to have reduced CD4<sup>+</sup> T cell values in earlier researches [5,8,34,43]. The most popular metric for assessing HIV progression, a patient's illness, and the ideal moment to start antiretroviral medication and preventive antibiotics is the absolute CD4<sup>+</sup> T cell count [20]. This antigen is also used in the laboratory staging of HIV infection. In a prior extensive nationwide investigation conducted in Nigeria, Oladepo et al. [49] showed that the typical reference range for absolute CD4<sup>+</sup> T cell counts in healthy persons was between 365 and 1571 cells/ $\mu\text{L}$ . For adult men and women in Nigeria, Aina et al. [50] similarly reported a reference range of 547–1327 cells/ $\mu\text{L}$ . Similar to these earlier studies, we found that normal, healthy control subjects had 350–1439 cells/ $\mu\text{L}$  of CD4<sup>+</sup> T cells in this study.

A prior study by Rahmana et al. [5] found a substantial correlation between declining CD4<sup>+</sup> T cell counts and an increase in anaemia, leucopenia, lymphopenia, and thrombocytopenia. Several other studies have reported a strong association between low CD4<sup>+</sup> T lymphocyte counts and an increased risk of haematological abnormalities among HIV-positive individuals undergoing antiretroviral therapy [29,30]. Anaemia, thrombocytopenia, and leucopenia have been consistently documented in individuals with advanced HIV disease, emphasizing the importance of monitoring these parameters during treatment.

Furthermore, the prevalence rates of anaemia, low PCV, and altered white blood cell and platelet counts in this study are in line with global trends reported in diverse populations [51]. The similarity in findings across different regions suggests that certain haematological changes are inherent to the HIV infection itself, while others may be influenced by factors such as nutritional status, co-infections, and genetic predispositions.

## 5. CONCLUSION

This research provides valuable insights into the haematological changes observed in HIV-positive patients receiving antiretroviral therapy in Edo State, Nigeria. The findings, particularly the association between CD4<sup>+</sup> T lymphocyte counts and various haematological parameters, are consistent with existing literature, highlighting the importance of regular monitoring and comprehensive care for HIV-positive individuals. These findings underscore the importance of considering both immunological and haematological parameters in the

management of HIV infection. Further research is warranted to explore the underlying mechanisms driving these observed differences and to develop targeted therapeutic strategies.

## 6. LIMITATION OF STUDY

The findings of our study may not be universally applicable due to its single center and hospital-based design among adults. It would be ideal to address the necessary gaps with a multicenter study with a significantly bigger sample size.

## REFERENCES

1. Federal Ministry of Health. Nigeria National Guidelines for HIV Prevention, Treatment and Care. National AIDS and STIs Control Programmes, Nigeria, 2016; 5-9.
2. CDC. 2021. About HIV/AIDS. <http://www.cdc.gov/hiv/basics/whatishiv.html>
3. UNAIDS. In Nigeria in 2018. <https://www.unaids.org/en/regionscountries/countries/nigeria>
4. Avert. HIV and AIDS in Nigeria. <http://www.avert.org/professionals/hiv-around-world/sub-Saharan-africa/nigeria>. 2022.
5. Rahmana MM, Giti S, Islam MS, Rahman MM. Haematological Changes in Peripheral Blood of HIV-Infected Persons with Correlation to CD4 Cell Count. *Journal of Bangladesh College of Physicians and Surgeons*, 2014;32, 130-136. <https://doi.org/10.3329/jbcps.v32i3.26050>
6. Anastos K, Shi Q, French LA, Levine A, Greenblatt MR, Williams C. Total Lymphocyte Count, Hemoglobin and Delayed-Type Hypersensitivity as Predictors of Death and AIDS Illness in HIV-1 Infected Women Receiving Highly Active Antiretroviral Therapy. *Journal of Acquired Immune Deficiency Syndromes*, 2014; 35, 383-392. <https://doi.org/10.1097/00126334-200404010-00008>
7. De Carvalho MJ. Retrospective Study on HIV/AIDS Associated Haematological Disorders Found in Bone Marrow at Dr George Mukhari Hospital (DGMH), Pretoria. Theses and Dissertations (Haematology). 2020.
8. Tagoe DNA, Asantewaa E. Profiling Haematological Changes in HIV Patients Attending Fevers Clinic at the Central Regional Hospital in Cape Coast, Ghana: A Case-Control Study. *Archives of Applied Science Research*, 2021;3, 326-331.
9. Belperio PS, Rhew DC. Prevalence and Outcomes of Anaemia in Individuals with Human Immunodeficiency Virus: A Systematic Review of the Literature. *The American Journal of Medicine*, 2014;116, 27S-43S. <https://doi.org/10.1016/j.amjmed.2003.12.010>
10. Munyazesa E, Emili I, Mutimura E, Hover DR, Shi Q, McGim AP. Assessment of Haematological Parameters in HIV-Infected and Uninfected Rwandan Women: A Cross-Sectional Study. *BMJ Open*, 2022;2, e001600. <https://doi.org/10.1136/bmjopen-2012-001600>
11. Adetifa IMO, Temiye EO, Akinsulie AO, Ezeaka VC, Iroha EO. Haematological Abnormalities Associated with Paediatric HIV/AIDS in Lagos. *Annals of Tropical Paediatrics*, 2016;2, 121-125. <https://doi.org/10.1179/146532806X107467>
12. Erhabor, O., Ejele, O.A., Nwauche, C.A. and Buseri, F.I. (2015) Some Haematological Parameters in Human Immunodeficiency Virus (HIV) Infected Africans: The Nigerian Perspective. *Nigerian Journal of Medicine*, 14, 33-38. <https://doi.org/10.4314/njm.v14i1.37132>

13. Parinitha SS, Kulkarni MH. Haematological Changes in HIV Infection with Correlation to CD4 Cell Count. *Australasian Medical Journal*, 2022;5, 157-162. <https://doi.org/10.4066/AMJ.2012.100>
14. Deayton J. High Prevalence of Lymphopenia on Full Blood Count at Time of First Diagnosis of HIV—A Potential Indicator of Undiagnosed HIV Infection. UK and Ireland Fellowship Programme. 2020.
15. Dangana A, Nuhu A, Thomas K. Evaluation of Haematological Variations among HIV Infected Patients Attending Antiretroviral Clinic at Barau Dikko Specialist Hospital Kaduna State Northwest Nigeria. *International Journal of Biomedical and Healthcare Science*, 2020;6, 215-217.
16. Agarwal MB. HIV/HAART Related Haematological Disorders: Diagnosis and Management. *Medicine Update* 2015;707-708.
17. Sullivan PS, Dworkin MS, Jones JL. Epidemiology of Thrombosis in HIV-Infected Individuals. *AIDS*, 2020;14, 321-324. <https://doi.org/10.1097/00002030-200002180-00015>
18. Bochen K, Krasowska A, Milariuk S, Kulczynska M, Pryskupa A, Dzida G. Erythrocyte Sedimentation Rate—An Old Marker with New Applications. *Journal of Pre-Clinical and Clinical Research*, 2021;5, 50-55.
19. Ashwini S, Madhuri T, Philip RA, Ramesh P. A Review on Peripheral Blood CD4<sup>+</sup> T Lymphocyte Counts in Healthy Adult Indians. *Indian Journal of Medical Research*, 2020;132, 667-675.
20. Idoko JA, Njoku MO, Sirisena MD, Jelpe D. CD4<sup>+</sup> T-Lymphocyte Counts in Human Immunodeficiency Virus (HIV) Infected Healthy Nigeria Population. *The Nigerian Medical Practitioner*, 2021;139, 53-56.
21. Ekeleme NC, Ijioma CE, Unachukwu NA, Ejikem PI, Areh JE, Ogwu CI, Jeffery EO, Esangbedo IJ, Amuta AC, Ojiri PC, Amoji NO, Aminu-Ayinde OE, Amadi ES, Onyeukwu N, Abali IO, Airaodion AI. Attitudes and Practices of Insecticide treated bed Nets Usage among Rural Dwellers in Oyo State, Nigeria. *International Journal of Tropical Diseases and Health*. 2023;44(15):43-58
22. Uduma VU, Ijioma CE, Ekeleme NC, Abali IO, Ejikem PI, Ogwu CI, Amuta AC, Areh JE, Odarah JE, Omole OR, Airaodion AI. Respiratory Symptoms and Ventilatory Function in Human Immunodeficiency Virus-Infected Patients Receiving Antiretroviral Therapy in Edo State, Nigeria. *Merit Research Journal of Medicine and Medical Sciences*, 2023;11(9):214-224.
23. Balogun TM, Alao AO, Olaosebikan OF, Aremu AJ, Adegbite OO. The Pattern of Haematological Changes in the Baseline Blood Cell Counts and the CD4<sup>+</sup> T Lymphocyte Levels among Antiretroviral Therapy Naïve Adult HIV Positive Patients in a Nigerian Hospital. *Open Journal of Blood Diseases*, 2020;10, 77-88. <https://doi.org/10.4236/ojbd.2020.103010>
24. Helleberg, M., Afzal, S., Kronborg, G, Larsen CS, Pedersen G, Pedersen C, Obel N. Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study. *Clinical Infectious Diseases*, 2023;56(5), 727-734.
25. Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. *American Journal of Public Health*, 2020;100(10), 1896-1903.

26. Samet JH, Cheng DM, Libman H, Nunes DP, Alperen JK, Saitz R, Mello MJ. Alcohol consumption and HIV disease progression. *Journal of Acquired Immune Deficiency Syndromes*, 2017; 46(2), 194-199
27. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Grinsztejn B. Prevention of HIV-1 infection with early antiretroviral therapy. *New England Journal of Medicine*, 2021;365(6), 493-505.
28. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *New England Journal of Medicine*, 2015;373(9), 795-807.
29. Smith MK, Sherr L, Johnson MO. A randomized controlled trial of a disclosure intervention for HIV+ mothers: The impact on depression and HIV medical outcomes. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 2019;80(2), 167-175.
30. Johnson MO, Chesney MA, Goldstein RB. Positive HIV status and adjustment to nonhomosexual social networks. *Archives of Sexual Behaviour*, 2020;49(4), 1113-1123.
31. Chen L, Wang J, Wang X, Wu Z, Li L. The changing epidemiology of HIV in Yunnan province, China, 1989–2016. *Scientific Reports*, 2018;8(1), 827.
32. Zhang F, Jing Y, Hui Y. CD4<sup>+</sup> T-lymphocyte dynamics in HIV-1-infected patients receiving antiretroviral therapy in Shanghai, China. *Journal of Medical Virology*, 2021;93(5), 3347-3354.
33. Kumar S, Kumar R, Gupta V. Hematological Changes in HIV Patients on Antiretroviral Therapy. *Journal of Clinical and Diagnostic Research*, 2020;14(7), OC01–OC04.
34. Bah G, Jaye A. Haematological Measurements and Iron Levels in HIV-Infected Gambian Subjects. *Retrovirology*, 2016;3, 4. <https://doi.org/10.1186/1742-4690-3-S1-P4>
35. Friel JT, Scadden TD. Haematological Manifestations of HIV Infection. 2021; <http://www.uptodate.com/contents/hematologic-manifestations-of-hiv-infection-anaemia>
36. Hoffbrand AV, Moss PAH, Pettit JE. *Essential Haematology*. 5th Edition, Blackwell Publishing, Oxford, 2016;328-329.
37. Groopman JE. Zidovudine Intolerance. *Reviews of Infectious Diseases*, 2020;12, S500-S506. [https://doi.org/10.1093/clinids/12.Supplement\\_5.S500](https://doi.org/10.1093/clinids/12.Supplement_5.S500)
38. De Angelis V, Biasinutto C, Pradella P, Errante D. Mixed-Type Auto-Immune Haemolytic Anaemia in a Patient with HIV Infection. *Vox Sanguinis*, 2020;68, 191-194. <https://doi.org/10.1159/000462926>
39. Ellaurie M, Burns ER, Rubinstein A. Hematologic Manifestations in Pediatric HIV Infection: Severe Anaemia as a Prognostic Factor. *The American Journal of Pediatric Hematology/Oncology*, 2020;12, 449-453. <https://doi.org/10.1097/00043426-199024000-00008>.
40. Makadzange AT, Ndhlovu CE, Takarinda KC. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa. *Clinical Infectious Diseases*, 2015;61(6), 897–905.
41. Morlat P, Roussillon C, Henard S, Salmon D. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. *AIDS*, 2017;31(5), 617–629.

42. Wong RS, Ho JT, Kew JH. (2019). Haematological manifestations of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. *Hematology Reviews*, 2019;11(2), 77–83.
43. Chukwuezi FO, Chukwuezi VI, Ezeifeka GO. Relationship between Haematological Values White Blood Cell (WBC), CD4 and HIV Infection in Individuals Not Yet on Anti-Retroviral in Onitsha Metropolis, Anambra State, Nigeria. *The Experiment*, 2023;13, 843-846.
44. Ellaine S. Haematologic Complications of HIV Infection. *AIDS Reviews*, 2015;7, 187-196.
45. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. *Current Opinion in HIV and AIDS*, 2018;13(2), 191–196.
46. Breckenridge MA, Okpanachi E. The Erythrocyte Sedimentation Rate in Healthy North Nigerian University Students. *African Journal of Medicine and Medical Sciences*, 2016;5, 221-227.
47. Obi GO. Normal Values for Haemoglobin Packed Cell Volume, and Erythrocyte Sedimentation Rate in Healthy Nigerian Adults. *African Journal of Medicine and Medical Sciences*, 2014;13, 1-6.
48. Abdulqadir I, Ahmed S, Kuliya A, Tukur J, Yusuf AA, Musa AU. Hematological Parameters of Human Immunodeficiency Virus Positive Pregnant Women on Antiretroviral Therapy in Aminu Kano Teaching Hospital Kano, North Western Nigeria. *Journal of Laboratory Physicians*, 2018;10, 60-63. [https://doi.org/10.4103/JLP.JLP\\_80\\_17](https://doi.org/10.4103/JLP.JLP_80_17)
49. Oladepo DK, Idigbe EO, Audu RA, Inyang US, Imade GE, Philip OA. Establishment of Reference Values of CD4 and CD8 Lymphocyte Subsets in Healthy Nigerian Adults. *Clinical and Vaccine Immunology*, 2019;16, 1374-1377. <https://doi.org/10.1128/CVI.00378-08>
50. Aina O, Dadik J, Charurat M, Amangaman P, Gurumdi S, Mang E. Reference Values of CD4<sup>+</sup> T Lymphocytes in Human Immunodeficiency Virus-Negative Adult Nigerians. *Clinical and Diagnostic Laboratory Immunology*, 2015;12, 525-530. <https://doi.org/10.1128/CDLI.12.4.525-530.2005>
51. Sullivan PS, Phaswana-Mafuya N, Baral SD, Valencia R, Zahn R, Dominguez K, Mastro TD. HIV prevalence, risks for HIV infection, and human rights among men who have sex with men (MSM) in Malawi, Namibia, and Botswana. *PLoS One*, 2021;16(4), e0250210.